Search

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 22, 2025 /PRNewswire/ -- https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ News Commentary -- Big developments are expected this week at [...]

Key Highlights: * Serplulimab was presented at the APA/JPS/CAP/IAP 2024 Annual Meeting for the first-line treatment of pancreatic cancer in combination with chemotherapy and radiotherapy. * HANSIZHUANG is an Anti-PD-1 [...]

LOS ALTOS: RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Ripal Gandhi, M.D., FSIR, FSVM will present at [...]

LUND, Sweden: Immunovia AB has issued the following news release: Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference [...]

CHICAGO: Actuate Therapeutics, Inc. (NASDAQ: ACTU) (Actuate or the Company), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen [...]

LUND, Sweden, Sept. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference in Cancer Research: [...]

LUND, Sweden: Immunovia AB has issued the following news release: Immunovia (Nasdaq Stockholm: IMMNOV), the pancreatic cancer diagnostics company, today presented detailed discovery study results for the company's next-generation early [...]

LUND, Sweden, July 25, 2024 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the pancreatic cancer diagnostics company, today presented detailed discovery study results for the company's next-generation early detection test for [...]

NEEDHAM, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=BJ3A0OrO_f-wXPQg6mv2G0hJZraJ9olJbcsag5_r4_WOUJh4Ju2isZB8jFUdcmamNhsEKIDjHNMxjNZeKV-MFboXY36ZB5-4m2jAps-yrIY= (Candel or the Company) (Nasdaq: https://www.globenewswire.com/Tracker?data=bOvCOn8tb4sPg3LFx9GxaXq7CMKysEwRPIQjxwSu7IHtB8PB9-GmGVHQpqMDkbX4K4StONo17_lJdYnKgmPAqchoS7S2GvVHv1M5Zaj1gdY=), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight [...]

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the [...]

TEL AVIV: BioLineRx has issued the following news release: BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced [...]

JERUSALEM: Alpha Tau Medical Ltd., the developer of Alpha DaRT, has presented new preclinical data at the 2024 European Society for Radiotherapy and Oncology congress in Glasgow, UK. The data [...]

SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the acceptance [...]

Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=3CLULKZwYT5HF3I_haAmgoto0d6jok9-uaA2wQOAlGa3sXybr8yaLlN9-W69P60095rqhE2yj3PIbtNiUqY_SNWrAqU9MBGLlOCvHvt6YIw= [...]

AUSTIN: PanTher Therapeutics (PanTher or the Company), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, today presented positive data from a first-in-human study of PTM-101, a [...]

CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from scientific collaborators at the [...]

ROOT, Switzerland--(BUSINESS WIRE)--Apr 5, 2024-- Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual [...]

Researchers Present Over 110 Studies Enabled by NanoString Platforms, including the new GeoMx IO Proteome Atlas and 6K Discovery Panel on the CosMx SMI SEATTLE -- NanoString Technologies, Inc., a [...]

WALTHAM: BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, has been selected for eight abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual [...]

PETACH TIKVA: Can-Fite BioPharma Ltd. announces its VP of Business Development, Dr. Sari Fishman, will present data from the pancreatic and liver cancer programs during numerous partnering meetings at the [...]

PETACH TIKVA, Israel -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases, today [...]

LOS ANGELES: Aadi Bioscience has issued the following news release: Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway [...]

Research pioneers, experts, and early career investigators unite LIVE in New York City for Seeing Beyond, honoring the organization's 25th anniversary year. NEW YORK, Nov. 20, 2023 /PRNewswire-PRWeb/ -- On [...]

DENVER: TriSalus Life Sciences Inc., an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced initial positive safety and [...]

- Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven tumor [...]

LEXINGTON: Agenus Inc., a leader in developing novel immunological agents to treat various cancers, announced that the Company will host a corporate event to discuss advancements in its botensilimab/balstilimab (BOT/BAL) [...]

One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation in pancreatic cancer [...]

Two p osters include data on potential clinical biomarkers and transcriptomic data associated with QN-302's mechanism of action CARLSBAD, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: [...]

TEL AVIV: BioLineRx Ltd has issued the following news release: BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today [...]

Abstracts to be Published on American Association of Cancer Research (AACR)Virtual Meeting Platform at 5:30 pm EDT on Wednesday, September 27, 2023 Oral Presentation on Thursday, September 28, 2023, in [...]

LOS ALTOS: RenovoRx, Inc (RNXT has announced that Shaun Bagai, CEO, will present at the 13th Annual LD Micro Invitational, held on June 6-8, 2023 at the Luxe Sunset Boulevard [...]

LOS ALTOS: RenovoRx, Inc. ('RenovoRx'), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that Shaun Bagai, CEO of RenovoRx, will present at the Aegis Capital Virtual [...]

HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, 'the Company'), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of [...]

* Next-generation anti-oxMIF antibody ON203 demonstrates anti-tumor effects through tumor cell death and modulation of the immunosuppressive tumor microenvironment in human tumoroids isolated from colorectal adenocarcinoma patients * First preclinical [...]

CHICAGO, Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking [...]

CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from scientific collaborators at the [...]

CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from scientific collaborators at the [...]

LOS ANGELES, CA -- The following information was released by UCLA Health System: The foundation hosts the annual Symposium on Pancreatic Cancer on March 11 at UCLA March 8, 2023 [...]

SAN DIEGO: Biological Dynamics, a company developing and commercializing its ExoVeritaTM platform for early disease diagnostics, announced that Harmeet Dhani, MD, MSc, Medical Director will present at the Precision Medicine [...]

BLACKSBURG, VA -- The following information was released by Virginia Tech: Speakers at the Fralin Biomedical Research Institute's event will share leading discoveries in substance use, neuroscience, pancreatic cancer, child [...]

SAN DIEGO: Oncolytics Biotech(r) Inc has issued the following news release: Oncolytics Biotech(r) Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic [...]

SAN DIEGO: Oncolytics Biotech(r) Inc. has issued the following news release: Oncolytics Biotech(r) Inc. (NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic [...]

70% objective response rate (ORR; n=10) is nearly triple the average ORR of ~25% reported in historical control trials[sup.1-4] Data suggest pelareorep synergizes with PD-(L)1 inhibitors and standard-of-care chemotherapy in [...]

Stockholm: Elekta AB has issued the following news release: Elekta (EKTA-B.ST) today announced two new reports from the MOMENTUM Study highlighting the clinical impact of Elekta Unity MR-Linac in treating [...]

- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the vulva at Addenbrookes Hospital in Cambridge - - Health Canada [...]